ArticleACS omega2026
Conformation-Specific Design: Engineering Extracellular Signal-Regulated Kinase 2 Variants with Bias toward Active or Inactive States.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Machine learning is revolutionizing protein design by enabling the rapid generation of sequences with precise structural and functional properties. Controlling protein conformational states remains a major challenge, particularly for enzymes regulated by complex structural switches. Here, using high-resolution structural data and probabilistic sequence-structure models, a machine learning-driven framework for conformationally biased protein design is presented titled Conformation-Specific Design or CSDesign. This approach generates sequences predicted to favor a desired conformation while disfavoring alternative states. As a proof-of-concept, this approach is applied to extracellular signal-regulated kinase 2 (ERK2), generating variants predicted to favor the active or inactive state. Experimental validation of relative kinase activity in a controlled assay confirmed that an active-biased variant, CSD104, exhibits robust kinase activity without native upstream phosphorylation, while an inactive-biased variant, CSD101, remains inactivated. Structural analysis suggests that engineered interactions stabilize active-like features in place of phosphorylation. These results demonstrate machine learning control of protein conformational ensembles, with potential to design enzymes and other conformationally regulated proteins without relying on phosphomimetic mutations or extensive experimental screening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.